Metastatic Melanoma: Chemotherapy to Biochemotherapy

O’Day, Steven; Kim, Christina J.; Reintgen, Douglas S.

doi:10.1177/107327480200900105

Cited by 54 publications

(41 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Response rates on traditional DTIC-based chemotherapy regimens are often low, with percentages below 10% [7]. Recent treatment with BRAF inhibitors or anti-CTLA4 has yielded response rates with a significant improvement in the 1-year survival, but the long-term survival benefits are to be awaited [8,9]. Moreover, these new agents may induce complications, with considerable morbidity and development of other skin cancers.…”

Section: Introductionmentioning

confidence: 99%

393. Hepatic resection for metastatic melanoma in the Netherlands – Survival and prognostic factors

Ridder

Walsum

Verhoef

et al. 2012

European Journal of Surgical Oncology

View full text Add to dashboard Cite

Patients with hepatic metastases of melanoma have a very poor prognosis, with a median overall survival of less than 6 months. There are several small heterogeneous studies that have shown an association with prolonged survival in those patients treated with hepatic resection, but the role of surgery remains unclear. We evaluated the safety and efficacy of hepatic resection in a population-based study in the Netherlands for patients with metastatic melanoma and assessed the factors that could affect disease-free and overall survival. Patients with hepatic melanoma metastases who underwent potentially curative resection were identified between 1994 until 2010 using the PALGA database, a nation-wide network and registry of histopathology and cytopathology in the Netherlands. They were retrospectively evaluated for clinical and pathological factors with respect to recurrence and survival using Kaplan-Meier curves to assess survival and univariate regression analysis for the assessment of potential prognostic factors. A total of 32 patients were identified in 15 hospitals, 19 men and 13 women. The median age of the patients at the time of hepatic resection was 52 years (range 27-69). Postoperative complications occurred in five patients (15%), without postoperative mortality. The median follow-up was 21 months (range 3-65). The median disease-free survival was 11 months (range 0-57) and the median overall survival was 29 months (range 4-66). Significant prognostic factors for overall survival in univariate analysis were the distribution and number of metastases, as well as the type of hepatic resection (major or minor). Hepatic resection in patients with resectable metastatic melanoma is safe and might be associated with a prolonged survival in a highly selected group of patients.

show abstract

Section: Introductionmentioning

confidence: 99%

393. Hepatic resection for metastatic melanoma in the Netherlands – Survival and prognostic factors

Ridder

Walsum

Verhoef

et al. 2012

European Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…It is ranked as the 5 th most common cancer in men and the 6 th most common cancer in women (Sober et al, 2008). Additionally, the 5-year survival for the metastatic melanoma is still significantly high, when compared to the non-metastatic type (O'Day et al, 2002). This is due, in part, to the relative resistance of metastatic melanoma to chemotherapeutic agents (O'Day et al, 2002).…”

Section: Introductionmentioning

confidence: 86%

“…Additionally, the 5-year survival for the metastatic melanoma is still significantly high, when compared to the non-metastatic type (O'Day et al, 2002). This is due, in part, to the relative resistance of metastatic melanoma to chemotherapeutic agents (O'Day et al, 2002). Thus, it is essential to develop new therapeutic agents targeting unique molecular signaling pathways important for the development of the malignant and invasive neoplasm.…”

Section: Introductionmentioning

confidence: 99%

Targeting Adenosine Receptors for the Treatment of Melanoma

Jajoo¹,

Sheth²,

Mukherjea³

et al. 2011

Breakthroughs in Melanoma Research

View full text Add to dashboard Cite

“…Among human cancers, melanoma appears to be uniquely suited to the use of this treatment modality, since this tumor tends to be highly immunogenic. 4,32 Intriguingly, an immunodominant epitope of the Melan A/MART-1 antigen is conserved in dogs, 22,34 and as it is in people, its expression may be prognostically significant. 35 The use of the biologic response modifiers IL-2 and interferon a (IFN-a) has been evaluated in various human clinical trials, with objective responses observed in 20-30% of patients.…”

Section: Discussionmentioning

confidence: 99%

Enhancing antimelanoma immune responses through apoptosis

et al. 2003

View full text Add to dashboard Cite

We examined the feasibility of using tumor apoptosis at accessible sites to enhance antimelanoma immune responses in a model of spontaneous canine melanoma. We show that priming peripheral blood mononuclear cells with apoptotic melanoma cells significantly enhanced autologous and allogeneic lymphokine-activated killing of tumor cells. Since various pathways required for intrinsic apoptosis are often inactivated in melanoma, we used Fas ligand (FasL) overexpression to promote extrinsic apoptosis. FasL induced apoptosis in five of six cell lines. Each of the susceptible lines, but not the resistant one, expressed Fas mRNA. In addition, direct intratumoral administration of FasL DNA to tumor-bearing dogs was safe, with no adverse events reported over 7 days of observation. A reduction of tumor burden was seen in three of five dogs treated. The reduction of tumor volume was correlated with Fas expression by the tumors, although one dog with a Fas-negative tumor survived for 82 weeks after treatment. Our data show that overexpression of FasL is suitable to promote apoptosis of Fas + melanomas, and support the notion that priming immune responder cells with apoptotic tumor cells may enhance antitumor responses. The results also suggest that intratumoral administration of FasL offers a safe route for therapeutic gene delivery.

show abstract

Metastatic Melanoma: Chemotherapy to Biochemotherapy

Abstract: Biochemotherapy remains a promising new treatment for metastatic melanoma. A large Intergroup trial E3695 comparing concurrent biochemotherapy to combination chemotherapy alone is powered to answer important survival questions.

Cited by 54 publications

References 37 publications

393. Hepatic resection for metastatic melanoma in the Netherlands – Survival and prognostic factors

393. Hepatic resection for metastatic melanoma in the Netherlands – Survival and prognostic factors

Targeting Adenosine Receptors for the Treatment of Melanoma

Enhancing antimelanoma immune responses through apoptosis

Contact Info

Product

Resources

About